Sit Investment Associates Inc. grew its stake in Agilent Technologies, Inc. (NYSE:A - Free Report) by 6.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 57,972 shares of the medical research company's stock after purchasing an additional 3,755 shares during the period. Sit Investment Associates Inc.'s holdings in Agilent Technologies were worth $7,788,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also modified their holdings of the company. State Street Corp boosted its holdings in shares of Agilent Technologies by 1.2% in the 3rd quarter. State Street Corp now owns 12,819,897 shares of the medical research company's stock worth $1,903,498,000 after acquiring an additional 158,175 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Agilent Technologies by 0.6% in the fourth quarter. Wellington Management Group LLP now owns 9,306,805 shares of the medical research company's stock valued at $1,250,276,000 after purchasing an additional 59,781 shares in the last quarter. Geode Capital Management LLC raised its position in Agilent Technologies by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 7,002,671 shares of the medical research company's stock worth $938,291,000 after purchasing an additional 53,992 shares during the last quarter. Pictet Asset Management Holding SA increased its stake in shares of Agilent Technologies by 0.9% in the 4th quarter. Pictet Asset Management Holding SA now owns 5,213,739 shares of the medical research company's stock valued at $700,414,000 after buying an additional 47,495 shares during the period. Finally, Norges Bank bought a new stake in Agilent Technologies during the 4th quarter worth about $456,963,000.
Insiders Place Their Bets
In related news, CEO Padraig Mcdonnell sold 1,911 shares of Agilent Technologies stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the sale, the chief executive officer now directly owns 39,652 shares of the company's stock, valued at approximately $5,947,800. This trade represents a 4.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Rodney Gonsalves sold 1,908 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $121.98, for a total value of $232,737.84. Following the transaction, the vice president now owns 21,786 shares in the company, valued at $2,657,456.28. The trade was a 8.05 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,638 shares of company stock valued at $731,229.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the company. TD Cowen upped their price objective on Agilent Technologies to $135.00 and gave the company a "buy" rating in a report on Thursday. StockNews.com upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a report on Tuesday, December 24th. Bank of America cut their target price on shares of Agilent Technologies from $153.00 to $150.00 and set a "neutral" rating on the stock in a report on Friday, December 13th. Robert W. Baird decreased their price target on shares of Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating for the company in a report on Thursday, February 27th. Finally, Barclays decreased their target price on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating for the company in a research note on Thursday. Seven research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Agilent Technologies presently has an average rating of "Moderate Buy" and an average target price of $146.25.
Get Our Latest Stock Analysis on Agilent Technologies
Agilent Technologies Stock Up 1.2 %
Agilent Technologies stock traded up $1.22 during mid-day trading on Friday, reaching $101.17. The company's stock had a trading volume of 818,038 shares, compared to its average volume of 1,843,645. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $155.35. The business's 50 day simple moving average is $124.64 and its 200 day simple moving average is $134.18. The company has a market capitalization of $28.84 billion, a price-to-earnings ratio of 23.21, a price-to-earnings-growth ratio of 3.00 and a beta of 1.19.
Agilent Technologies (NYSE:A - Get Free Report) last released its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. The business had revenue of $1.68 billion for the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. As a group, research analysts anticipate that Agilent Technologies, Inc. will post 5.57 earnings per share for the current year.
Agilent Technologies Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be issued a dividend of $0.248 per share. The ex-dividend date of this dividend is Tuesday, April 1st. This represents a $0.99 dividend on an annualized basis and a yield of 0.98%. Agilent Technologies's payout ratio is 22.76%.
About Agilent Technologies
(
Free Report)
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.
See Also
Before you consider Agilent Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.
While Agilent Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
